68Ga-RM26-RGD PET/CT Imaging in the GRPR and αvβ3 Positive Tumor Patients
Based on the high expression of specific receptors on the surface of diseased tissues and neovascularization, noninvasive targeted molecular imaging can be used to visualize lesions in vitro by combining specific ligands labeled with short half-life isotopes. In this study, a novel dual-target imaging agent 68Ga-RM26-RGD was used for clinical study of tumor PET/CT imaging to further verify its clinical application value.
Conditions studied
Breast Cancer, Prostate Cancer, Brain Tumor, PET/CT Imaging
About this study
Based on the high expression of specific receptors on the surface of diseased tissues and neovascularization, noninvasive targeted molecular imaging can be used to visualize lesions in vitro by combining specific ligands labeled with short half-life isotopes. In this study, a novel dual-target imaging agent 68Ga-RM26-RGD was used for clinical study of tumor PET/CT imaging to further verify its clinical application value.
Interventions
- Drug: 68Ga-RM26-RGD — Intravenous injection of 68Ga-RM26-RGD with a dosage of approximately 1.8-2.2 MBq (0.05-0.06 mCi)/ kg.
- Drug: 18F-FDG — 18F-FDG injection
- Drug: 68Ga-RM26 — Intravenous injection of 68Ga-RM26-RGD with a dosage of approximately 1.8-2.2 MBq (0.05-0.06 mCi)/ kg.
- Drug: 68Ga-RGD — Intravenous injection of 68Ga-RGD with a dosage of approximately 1.8-2.2 MBq (0.05-0.06 mCi)/ kg.
Primary outcomes
- Diagnostic performance1 (through study completion, an average of 1 year)
- Diagnostic performance2 (through study completion, an average of 1 year)
- Diagnostic performance3 (through study completion, an average of 1 year)
Eligibility information
Study locations
- Peking Union Medical College Hospital, Beijing, China
Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-09-27.